Biome Australia (BIO) Q1 2026 TU earnings summary

Executive summary

• Achieved a record-breaking Q1 FY 2026 with $5.94 million in sales revenue, up 40% year-over-year and 19% quarter-on-quarter, and the first full-year net profit in FY 2025.

• Focused on clinically proven, condition-specific probiotics and therapeutics, distributed through over 6,000 health retail outlets in Australia.

• International expansion progressing in Canada, Ireland, New Zealand, and Europe, with strong early results and new distribution deals.

• Launched four new Activated Therapeutics products targeting gut health, perimenopausal symptoms, GLP-1 support, and gastric reflux.

• Rolling 12-month sales revenue surpassed $20 million, with an annualized run-rate of $24 million based on Q1.

Financial highlights

• Q1 FY 2026 sales annualized at $24 million, with $462,000 EBITDA for the quarter and seven consecutive quarters of positive EBITDA.

• Cash receipts for Q1 reached $7.14 million, up 84% year-over-year, with net operating cash inflow of $918,000.

• Gross margin maintained above 61%, industry-leading in the category.

• Cash balance increased to $2.94 million at September 30, 2025, after paying down working capital lines.

• Inventory at quarter-end was $3.4 million, with a wholesale value of $8.5 million.

Outlook and guidance

• On track to achieve Vision 27 target of $75 million cumulative sales from FY 2025 to FY 2027.

• Distribution points expected to grow from 5,000 to 8,000 in Australia, with international markets set to deliver strong performance in FY 2026.

• Continued focus on innovation, new clinical trials, and expanding product portfolio.